Delonix Bioworks and A*STAR Infectious Diseases Labs Announce Research Collaboration to Advance Novel Engineered OMV Vaccine Candidates Against Klebsiella pneumoniae
SHANGHAI and SINGAPORE, Nov. 16, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering next-generation outer membrane vesicle (OMV) vaccines, today announced that it has entered into a Research Collaboration Agreement with A*STAR Infectious Diseases Labs (A*STAR IDL), a research institute under Singapore's Agency for Science, Technology and Research (A*STAR).
The collaboration aims to discover and develop novel OMV-based vaccine candidates targeting Klebsiella pneumoniae (K. pneumoniae). By combining Delonix's proprietary pathogenic bacterial genome editing and OMV Plus™ platforms with A*STAR IDL's strong capabilities in translational infectious disease research, clinical relevant bacterial isolates, and immunological evaluation, the collaboration also strengthens Singapore's capabilities to translate infectious disease research towards potential interventions against antimicrobial-resistant pathogens.
K. pneumoniae is a leading cause of life-threatening pneumonia, bloodstream infections, and sepsis, posing severe risks to vulnerable patient populations. The World Health Organization (WHO) has classified carbapenem-resistant Enterobacterales, including K. pneumoniae, as critical-priority pathogens due to high levels of multi-drug resistance against standard clinical therapies [1,2,3].
Despite the significant public health burden, there are currently no licensed vaccines available for K. pneumoniae. Traditional vaccine approaches have been hindered by the pathogen's extensive genetic diversity, thick capsular polysaccharides that mask conserved surface antigens, and high antigenic variation across hypervirulent and multidrug-resistant clinical lineages. Delonix's engineered OMV approach offers a differentiated solution to overcome these barriers. By precisely editing the bacterial genome to modulate capsular interference, detoxify endotoxins, and enrich conserved native antigens on non-replicating vesicles, engineered OMVs has the potential to elicit potent innate and adaptive immune responses capable of broad cross-strain protection.
This partnership marks an important milestone in Delonix's global strategy to build collaborative networks that accelerate the translation of next-generation bacterial vaccines. Driven by a shared commitment to combating antimicrobial resistance (AMR), Delonix and A*STAR IDL will leverage their complementary strengths to generate and evaluate vaccine candidates for safety, immunogenicity, and broad cross-strain protective potential, with the aim of advancing potential preventive approaches against drug-resistant K. pneumoniae.
About Delonix Bioworks
Delonix Bioworks is a clinical-stage biotechnology company at the forefront of developing next-generation genetically engineered bacterial vaccines. Leveraging its proprietary OMV Plus™ platform, the company produces high-yield, cost-effective, and precisely engineered outer membrane vesicles (OMVs) designed for superior antigen presentation and immunogenicity. Delonix is dedicated to advancing a robust pipeline of innovative bacterial vaccine candidates addressing critical unmet needs, including vaccines targeting meningococcal group B (MenB), pertussis, gonorrhoea, and K. pneumoniae infections. Its lead candidate, DX-104, is currently in Phase I clinical trials in Australia and China.
For more information, please visit https://delonixbio.com/.
Business Development & Strategic Partnerships
Email: bd@delonixbio.com
| References |
| [1] WHO. WHO Bacterial Priority Pathogens List, 2024. |
| [2] WHO. Global Antibiotic Resistance Surveillance Report 2025. |
| [3] WHO. WHO Warns of Widespread Resistance to Common Antibiotics Worldwide. 2025. |
- 発信企業・団体
- Delonix Bioworks
- 業種カテゴリ
- 医療・健康・介護
- 発表日時
- 2026-11-16 22:00 (JST) 原文: 2026-11-16 21:00 (+08:00)
- 原文
- 配信元のページを開く
本記事はPR Newswireより配信されたプレスリリースを原文のまま掲載したものです。 内容に関する責任は発信者に帰属し、当サイトは記載内容の正確性を保証しません。 掲載内容に関するお問い合わせは お問い合わせ よりご連絡ください。